Journal Information
Share
Share
Download PDF
More article options
Visits
44
Original article
DOI: 10.1016/j.bjid.2019.01.007
Open Access
Uncorrected Proof. Available online 1 March 2019
Hepatitis E virus prevalence in Egyptian children with transfusion-dependent thalassemia
Visits
44
Doaa Abdelmawlaa, Dalia Moemena,
Corresponding author
dr_daliamoemen@yahoo.com

Corresponding author.
, Ahmad Darwishb, Wafaa Mowafya
a Mansoura University, Faculty of Medicine, Department of Medical Microbiology and Immunology, Mansoura, Egypt
b Mansoura University, Faculty of Medicine, Department of Pediatrics, Mansoura, Egypt
This item has received
44
Visits

Under a Creative Commons license
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (3)
Table 1. Demographic data associated with HEV seropositivity in thalassemic children.
Table 2. Clinical parameters associated with HEV seropositivity in thalessemic children.
Table 3. Univariate and multivariate analyses of factors associated with HEV seropositivity in thalassemic children.
Show moreShow less
Abstract

Hepatitis E virus (HEV) infection is one of the major public health problems in developing countries. HEV can cause chronic infections in immunocompromised individuals e.g. thalassemic patients with increased risk of morbidity and mortality. In addition there is possibility of HEV transmission through blood transfusion. Therefore, the present study aimed to investigate the seroprevalence and risk factors of HEV infection in β-thalassemic children.

Methods

This cross-sectional study was conducted on 140 Egyptian children suffering from β-thalassemia, attending the hematology outpatient clinic from April to October 2016. Serum samples from patients were collected and anti-HEV antibodies (IgG and IgM) were measured by enzyme-linked immunosorbent assay (ELISA).

Results

The seroprevalence of HEV in β-thalassemic chidren was relatively high (27.15%). Anti-HEV IgG prevalence was 24.29% while that of IgM was 2.86%. There was significant association between HEV infection and age, residence, liver enzymes and amount of blood transfusion per year.

Conclusions

Thalasemic patients are vulnerable to chronicity and increased risk of morbidity and mortality from HEV infection. Frequent assessment of liver enzymes in thalassemic patients to monitor subclinical HEV is recommended. Close monitoring and HEV screening of blood donations should be taken in consideration. Public awareness about HEV endemicity, modes of transmission, and risk hazards especially in high risk group should be done to reduce the disease burden.

Keywords:
Hepatitis E virus (HEV)
Prevalence
Thalassemia
Transfusion
Full Text
Introduction

Hepatitis E virus infection is endemic in many developing countries while sporadic HEV infections have also been reported in some developed countries.1 Although HEV infection is usually associated with acute self-limited hepatitis, fulminant hepatic failure with morbidity and mortality may occur especially in immunocompromised hosts.2 High prevalence of HEV infection was reported in Africa, Central and Southeast Asia, and Mexico.3 In France, the seroprevalence of HEV (anti-HEV immunoglobulin G (IgG) and IgM) varied from 21.9% to 71.3%, according to geographic distribution, with average 39.1%.4 People with low educational level may be at a higher risk of exposure and infection than those with higher educational level. In Egypt, low educational level and socioeconomic status resulted in lack of knowledge about avoidable possible risk factors associated with HEV infection. Thus HEV was highly endemic in Egyptian rural communities with genotype 1 subtype 3 most circulating.5,6 There are four documented routes of transmission of HEV including fecal-oral route, vehicle-borne including water-borne and zoonotic foodborne, bloodborne transmission through parenteral blood transfusion, and perinatal via vertical transmission from mother-to-infant.7,8 Chronic HEV infection was acquired in 1.4% of patients following liver transplantion which subsequently resulted in persistent damage of the liver graft.9 Thalassemia is one of the most common genetic diseases worldwide. It is a major public health problem, causing much morbidity, early mortality, and great financial and emotional burden for a family. Thalassemia is the most common form of inherited anemia around the world.10 β-thalassemia frequencies are common in almost all Arab countries.11 In Egypt, β-thalassemia is the most common type with a carrier rate ranging from 5.3% to ≥9%. It was estimated that 1000/1.5 million live births/year suffer from thalassemia disease in Egypt.12 Many thalassemia patients develop chronic liver disease (CLD) like chronic hepatitis C. HAV and HEV infections show more severe clinical courses in the CLD patients.13 Some authors documented HEV seropositivity among hemodialysis and thalassemia patients.14,15 It was reported that HEV RNA detected in blood donations through studies by blood banks in several European countries.16 Therefore, some countries began HEV RNA screening of blood donations and others selectively applied blood screening for high risk patients.17 A previous study conducted on patients with acute viral hepatitis in Egypt reported HEV infection in about 12–42% of all cases.18 Another study carried out on blood samples collected from 134 jaundiced patients in Egypt, revealed that 51 (38.1%) patients were positive for anti-HEV IgG.19 Also, study on children with acute viral hepatitis in Assiut, Egypt, detected 30.9% HEV infection in children.20 The present study aimed to detect the seroprevalence of HEV infection in thalassemic children to assess the role of blood transfusion as a risk factor for HEV infection.

Patients and methodsPatients

This cross-sectional study was conducted on 140 Egyptian children suffering from β-thalassemia, attending the hematology outpatient clinic in Mansoura University Children's Hospital (MUCH) from April 2016 through October 2016. Patients included in this study were patients with beta-thalassemia aged up to 18 years who frequently received blood transfusion. However, patients with hemolytic anemia other than thalassemia, patients with alpha-thalassemia, and patients with less than 10 blood transfusions were excluded from the study. This study was approved by the Medical Research Ethics Committee, Mansoura University (IRB no. MS/16/03/82).

Data collected from patients

Data collected from patients included age, sex, residence, amount of blood transfused per year, abdominal examination of liver and spleen, serum ferritin, liver function tests (ALT and AST), and viral hepatitis markers (HBs Ag and HCV Abs).

Sample collection and processing

Two milliliters of venous blood were obtained from each selected patient and collected in a sterile tube, centrifuged immediately for serum separation. Serum samples were stored at −20°C. Presence of anti-HEV antibodies (anti-HEV IgG indicating past infection and anti-HEV IgM indicating recent infection) in the patients’ sera were measured by enzyme-linked immunosorbent assay; HEV-IGM Elisa (Immunospec, USA, BL147710) and HEV-IGG Elisa (Immunospec, USA, BL147709).

Statistical analysis

The collected data was coded, processed and analyzed using SPSS (Statistical package for social science) version 23 for windows. Descriptive statistics were calculated as mean±standard deviation (SD), median, interquartile range (IQR), and frequency (number-percent). Parametric Student's t-test (unpaired) and non-parametric Mann Whitney test were used as appropriate to compare means of continuous variables of two different groups. Chi square test was used for inter-group comparison of categorical data. p-Value less than 0.05 (5%) was considered statistically significant. Significant variables on univariate analysis were entered into a logistic regression model to determine which of these factors were independently associated with HEV infection.

Results

The seroprevalence of HEV antibodies in β-thalassemic patients was 27.15% (38/140 patients); 34 (24.29%) patients were positive for anti-HEV IgG, and four (2.86%) patients were positive for anti-HEV IgM. As shown in Table 1, there was significant association between age and anti-HEV IgG and IgM seropositivity (p=0.004, and 0.044, respectively). HEV seropositivity increased with age. There was significant association between rural residence and anti-HEV IgG (p<0.001). Regarding clinical data, there was significant association between liver enzymes and anti-HEV IgG. No patients in our study had HBV infection. Splenectomy was significantly associated with HCV and HEV infection (Table 2). Table 3. In Univariate analysis, there was significant association between Age, residence, liver enzymes, and amount of blood transfusions per year were significantly associated with HEV seropositivity on univariate analysis. On multivariate analysis only rural residence and elevated ALT levels were independently associated with HEV seropositivity.

Table 1.

Demographic data associated with HEV seropositivity in thalassemic children.

Demographic dataAnti-HEV IgGAnti-HEV IgM
    Positive (n=34)  Negative (n=106)  p-Value  Positive (n=4)  Negative (n=136)  p-Value 
Age range (years)2–6  5 (14.7%)  33 (31.1%)  0.004a0 (0.0%)  38 (27.9%)  0.044a
6–12  14 (41.2%)  55 (51.9%)  1 (25.0%)  68 (50.0%) 
12–18  15 (44.1%)  18 (17.0%)  3 (75.0%)  30 (22.1%) 
SexFemale  16 (47.1%)  49 (46.2%)  0.9331 (25.0%)  64 (47.1%)  0.383
Male  18 (52.9%)  57 (53.8%)  3 (75.0%)  72 (52.9%) 
ResidenceRural  28 (82.4%)  51 (48.1%)  <0.001b3 (75.0%)  76 (55.9%)  0.447
Urban  6 (17.6%)  55 (51.9%)  1 (25.0%)  60 (44.1%) 

n, number.

a

Significance <0.05.

b

High significance.

Table 2.

Clinical parameters associated with HEV seropositivity in thalessemic children.

Clinical dataAnti-HEV IgGAnti-HEV IgM
    Positive (n=34)  Negative (n=106)  p-Value  Positive (n=4)  Negative (n=136)  p-Value 
Splen-ectomyYes  16 (47.1%)  42 (39.6%)  0.4442 (50.0%)  56 (41.2%)  0.724
No  18 (52.9%)  64 (60.4%)  2 (50.0%)  80 (58.8%) 
HCVPositive  11 (32.4%)  25 (23.6%)  0.3091 (25.0%)  35 (25.7%)  0.974
Negative  23 (67.6%)  81 (76.4%)  3 (75.0%)  101 (74.3%) 
HBVPositive  0 (0.0%)  0 (0.0%)  0 (0.0%)  0 (0.0%) 
Negative  34 (100.0%)  106 (100.0%)  4 (100.0%)  136 (100.0%) 
ALTElevated  28 (82.4%)  47 (44.3%)  <0.001b4 (100.0%)  71 (52.2%)  0.059
Normal  6 (17.6%)  59 (55.7%)  0 (0.0%)  65 (47.8%) 
ASTElevated  23 (67.6%)  39 (36.8%)  0.002a3 (75.0%)  59 (43.4%)  0.210
Normal  11 (32.4%)  67 (63.2%)  1 (25.0%)  77 (56.6%) 

ALT, alanine transaminase; AST, aspartate transaminase; n, number.

a

Significance <0.05.

b

High significance.

Table 3.

Univariate and multivariate analyses of factors associated with HEV seropositivity in thalassemic children.

  Univariate analysisMultivariate analysis
  p Value  OR  95% C.I.  p Value  OR  95% C.I. 
Age (years)  0.001a  1.18  1.07–1.29       
Male sex  0.807  1.098  0.52–2.32       
Rural Residence  0.001a  4.98  2.01–12.35  0.003a  4.277  1.65–11.09 
Splenectomy  0.385  1.39  0.66–2.96       
Abnormal AST  0.001a  3.97  1.79–8.80       
Abnormal ALT  <0.001a  7.32  2.81–19.04  <0.001b  6.486  2.43–17.32 
Amount of blood transfused (mL/year)  0.008a  1.00  1.00–1.00       
Serum ferritin (μg/L)  0.313  1.00  1.00–1.00       

ALT, Alanine transaminase; AST, Aspartate transaminase; p, probability; OR, odd's ratio; CI, confidence interval.

Discussion

The prevalence of HEV antibodies among thalassemic children in our study was 27.15%, 24.29% anti-HEV IgG positive and 2.86% anti-HEV IgM positive. Results of previous studies showed seroprevalence of HEV antibodies of 2.4% in thalassemic patients in Scandinavia21 and 10.7% in Saudi Arabia.22 In Iran, the seroprevalence of HEV IgG and HEV IgM were 10% and 1.8%, respectively.23 Reasons such as differences in socioeconomic, cultural, hygienic, and climatic factors across geographical areas may explain the lower prevalence rates in developed countries compared to developing countries.24 In our study, age was significantly associated with HEV antibodies. The highest HEV prevalence rate found in the age group 12–18 years indicated that the risk of HEV infection increased with age. Previous studies carried out in Egypt25 and in other geographic regions reported the same finding.26–28 This could be explained by the fact that older children had likely received more transfused blood, in addition to have been more exposed to contaminated junk food than younger children. In this study, the prevalence of HEV antibodies in rural areas (81.6%) was higher than in urban areas (18.4%), respectively. In rural Egypt, more than 60% of children with aged over 10 years had positive anti-HEV IgG.29 On the contrary, another study conducted on HCV infected thalassemic patients in Iran reported higher HEV seropositivity in thalassemic patients from urban regions than those from rural areas.6 Regarding liver enzymes, 84.2% of patients with HEV seropositivity showed elevated ALT levels, compared to 68.4% of elevated AST levels. Liver enzymes were higher among those with non-HEV antibodies compared to those with HEV antibodies. This may be due to presence of other causes of hepatitis either viral causes, mostly HCV, or non-viral causes. Although 100% and 75% of anti-HEV IgM positive patients had elevated ALT and AST levels, respectively, there was no significant association between liver enzymes and anti-HEV IgM seropositivity, probably due to small number of anti-HEV IgM positive patients. Previous studies reported that subclinical HEV infection might be the cause of elevated ALT.30 Therefore, in cases of unexplained ALT and AST elevation, HEV may be the reasonable cause. In two studies conducted in Japan on voluntary blood donors with elevated ALT levels, anti-HEV IgG was positive in 3.7% and 7.1% of participants.31,32 These findings suggest that patients with ongoing subclinical HEV infection had the potential to transmit HEV through blood transfusion. Our study revealed that there was significant association between the amount of blood transfused per year and HEV seropositivity (p=0.008). On the other hand, a previous study showed no significant association between the amount of blood transfused and anti-HEV seropositivity in thalassemic patients.21 This difference may be due to geographic difference and use of assays with low sensitivity that could underestimate HEV prevalence.33 Studies conducted in blood banks of several European countries reported that about 0.02–0.14% of blood donations were HEV RNA positive.16,34 This finding supports the possibility of HEV transmission through blood transfusion. Since recently in Ireland, blood donations are routinely screened for HEV RNA. Also in 2017, the UK, and Netherlands began HEV RNA screening in blood donations. In France and Germany, screening selectively occurs in high-risk patients, while blood authorities in Italy, Spain, Portugal and Greece are assessing whether HEV screening should be implemented or not.17 A previous study conducted in Egypt showed that about 0.45% of blood donors have ongoing subclinical HEV infection.35 It was reported that the risk of transmission through blood transfusion is increased in high-risk patients in developing regions than in other locations.23 HEV is endemic in Egypt and besides the possibility of HEV transmission through blood, our study showed significant association between amount of blood transfused and HEV seropositivity. Therefore, further studies should be carried out to detect HEV infection in risk group patients and blood donors.

Conclusion

In conclusion, the seroprevalence of HEV in β-thalassemic patients was relatively high. Therefore, close monitoring of these patients in addition to HEV screening of blood donations should be taken into consideration. Frequent assessment of liver enzymes in β-thalassemic patients to monitor subclinical HEV infections and other viral infections is recommended. Public awareness about HEV endemicity, modes of transmission, and risk hazards, especially in high-risk groups should be done to reduce the disease burden.

Funding

None declared.

Conflicts of interest

The authors declare no conflicts of interest.

References
[1]
L. Romano’, S. Paladini, C. Tagliacarne, M. Canuti, S. Bianchi, A.R. Zanetti
Hepatitis E in Italy: a long-term prospective study
[2]
J.E. Arends, V. Ghisetti, W. Irving
Hepatitis E: an emerging infection in high income countries
J Clin Virol, 59 (2014), pp. 81-88 http://dx.doi.org/10.1016/j.jcv.2013.11.013
[3]
M.S. Balayan
Epidemiology of hepatitis E virus infection
J Viral Hepatitis, 4 (1997), pp. 155-165
[4]
P. Clemente Casares, C. Ramos Romero, E. Ramirez Gonzalez, A. Mas
Hepatitis E virus in industrialized countries: the silent threat
BioMed Res Int, (2016), pp. 9838041
[5]
A.F. Amer, S.A. Zaki, A.M. Nagati, M.A. Darwish
Hepatitis E antibodies in Egyptian adolescent females: their prevalence and possible relevance
J Egypt Public Health Assoc, 71 (1996), pp. 273-284
[6]
P.K. Elizee, S.M. Alavian, S.M. Miri
The seroprevalence of entrically transmitted viral hepatitis in HCV infected thalassemia and hemophilia patients in Iran
Jundishapur J Microbiol, 6 (2013), pp. e9091
[7]
I.K. Mushahwar
Hepatitis E virus: molecular virology clinical features, diagnosis, transmission, epidemiology, and prevention
J Med Virol, 80 (2008), pp. 646-658 http://dx.doi.org/10.1002/jmv.21116
[8]
H.C. Lewis, O. Wichmann, E. Duizer
Transmission routes and risk factors for autochthonous hepatitis E virus infection in Europe: a systematic review
Epidemiol Infect, 138 (2010), pp. 145-166 http://dx.doi.org/10.1017/S0950268809990847
[9]
C. Feray, J.M. Pawlotsky, A.M. Roque-Afonso, D. Samuel, D. Dhumeaux
Should we screen blood products for hepatitis E virus RNA?
[10]
L. Quek, S.L. Thein
Molecular therapies in beta-thalassaemia
Br J Haematol, 136 (2007), pp. 353-365 http://dx.doi.org/10.1111/j.1365-2141.2006.06408.x
[11]
H.A. Hamamy, N.A. Al-Allawi
Epidemiological profile of common haemoglobinopathies in Arab countries
J Commun Genet, 4 (2013), pp. 147-167
[12]
A. El-Beshlawy, I. Youssry
Prevention of hemoglobinopathies in Egypt
Hemoglobin, 33 (2009), pp. S14-S20 http://dx.doi.org/10.3109/03630260903346395
[13]
H.C. Cho, S.W. Paik, Y.J. Kim
Seroprevalence of anti-HAV among patients with chronic viral liver disease
World J Gastroenterol, 17 (2011), pp. 236-241 http://dx.doi.org/10.3748/wjg.v17.i2.236
[14]
P. Morteza, S. AbdolReza, N. Hamid
Hepatitis E virus infection in hemodialysis patients: a seroepidemiological survey in Jahrom, Southern Iran
Hepatitis Mon, 3 (2009), pp. 232-235
[15]
A.S. Jahromi, A. Ahmadi-Vasmehjani, H. Zabetian
Sero-epidemiological study of hepatitis E virus among Thalassemia as high risk patients: a cross-sectional survey in Jahrom, Southern Iran
Global J Health Sci, 8 (2016), pp. 245-250
[16]
P. Gallian, A. Couchouron, I. Dupont
Comparison of hepatitis E virus nucleic acid test screening platforms and RNA prevalence in French blood donors
Transfusion, 57 (2017), pp. 223-224 http://dx.doi.org/10.1111/trf.13889
[17]
D. Domanovic, R. Tedder, J. Blumel
Hepatitis E and blood donation safety in selected European countries: a shift to screening?
[18]
S. Zakaria, R. Fouad, O. Shaker
Changing patterns of acute viral hepatitis at a major urban referral center in Egypt
Clin Infect Dis, 44 (2007), pp. e30-e36 http://dx.doi.org/10.1086/511074
[19]
W.F. El-Tras, A.A. Tayel, N.N. El-Kady
Seroprevalence of hepatitis E virus in humans and geographically matched food animals in Egypt
Zoonoses Public Health, 60 (2013), pp. 244-251 http://dx.doi.org/10.1111/j.1863-2378.2012.01516.x
[20]
G. Hasan, A. Assiri, N. Marzuuk
Incidence and characteristics of hepatitis E virus infection in children in Assiut Upper Egypt
J Int Med Res, 44 (2016), pp. 1115-1122 http://dx.doi.org/10.1177/0300060516659575
[21]
M. Psichogiou, E. Tzala, J. Boletis
Hepatitis E virus infection in individuals at high risk of transmission of non-A, non-B hepatitis and sexually transmitted diseases
Scand J Infect Dis, 28 (1996), pp. 443-445 http://dx.doi.org/10.3109/00365549609037936
[22]
I. Al-Fawaz, S. Al-Rasheed, M. Al-Mugeiren, A. Al-Salloum, M. Al-Sohaibani, S. Ramia
Hepatitis E virus infection in patients from Saudi Arabia with sickle cell anaemia and beta-thalassemia major: possible transmission by blood transfusion
J Viral Hepatitis, 3 (1996), pp. 203-205
[23]
A. Sotoodeh Jahromi, A. Ahmadi-Vasmehjani, H. Zabetian
Sero-epidemiological study of hepatitis E virus among thalassemia as high risk patients: a cross-sectional survey in Jahrom, Southern Iran
Glob J Health Sci, 8 (2016), pp. 53885 http://dx.doi.org/10.5539/gjhs.v8n9p245
[24]
S.A. Junaid, S.E. Agina, K.A. Abubakar
Epidemiology and associated risk factors of hepatitis e virus infection in plateau state Nigeria
Virology (Auckl), 5 (2014), pp. 15-26
[25]
S.K. Stoszek, R.E. Engle, M. Abdel-Hamid
Hepatitis E antibody seroconversion without disease in highly endemic rural Egyptian communities
Trans R Soc Trop Med Hyg, 100 (2006), pp. 89-94 http://dx.doi.org/10.1016/j.trstmh.2005.05.019
[26]
C. Dong, X. Dai, J.S. Shao, K. Hu, J.H. Meng
Identification of genetic diversity of hepatitis E virus (HEV) and determination of the seroprevalence of HEV in eastern China
Arch Virol, 152 (2007), pp. 739-746 http://dx.doi.org/10.1007/s00705-006-0882-0
[27]
M. Taremi, A.H. Mohammad Alizadeh, A. Ardalan, S. Ansari, M.R. Zali
Seroprevalence of hepatitis E in Nahavand Islamic Republic of Iran: a population-based study
East Mediterr Health J, 14 (2008), pp. 157-162
[28]
D.A. Anderson 7th
Hepatitis E virus
Mandell, Douglas, and Bennett's principles and practice of infectious diseases, pp. 2411-2423
[29]
A.D. Fix, M. Abdel-Hamid, R.H. Purcell
Prevalence of antibodies to hepatitis E in two rural Egyptian communities
Am J Trop Med Hyg, 62 (2000), pp. 519-523
[30]
D. Gao, G. Peng, J. Zhu, L. Sun, Y. Zheng, J. Zhang
Investigation of sub-clinical infection of hepatitis E virus in blood donors
Chin J Hepatol, 12 (2004), pp. 11-12
[31]
S. Fukuda, J. Sunaga, N. Saito
Prevalence of antibodies to hepatitis E virus among Japanese blood donors: identification of three blood donors infected with a genotype 3 hepatitis E virus
J Med Virol, 73 (2004), pp. 554-561 http://dx.doi.org/10.1002/jmv.20125
[32]
Y. Gotanda, A. Iwata, H. Ohnuma
Ongoing subclinical infection of hepatitis E virus among blood donors with an elevated alanine aminotransferase level in Japan
J Med Virol, 79 (2007), pp. 734-742 http://dx.doi.org/10.1002/jmv.20834
[33]
A. Avellon, L. Morago, M. Garcia-Galera del Carmen, M. Munoz, J.M. Echevarria
Comparative sensitivity of commercial tests for hepatitis E genotype 3 virus antibody detection
J Med Virol, 87 (2015), pp. 1934-1939 http://dx.doi.org/10.1002/jmv.24251
[34]
B.M. Hogema, M. Molier, M. Sjerps
Incidence and duration of hepatitis E virus infection in Dutch blood donors
Transfusion, 56 (2016), pp. 722-728 http://dx.doi.org/10.1111/trf.13402
[35]
E.H. Ibrahim, S.F. Abdelwahab, S. Nady
Prevalence of anti-HEV IgM among blood donors in Egypt
Egypt J Immunol, 18 (2011), pp. 47-58
Copyright © 2019. Sociedade Brasileira de Infectologia
The Brazilian Journal of Infectious Diseases

Subscribe to our newsletter

Article options
Tools
Cookies policy
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.